You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lanreotide

Showing 26 - 50 of 119
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Thyroid-Associated Ophthalmopathy Trial in Alicante (Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1

Terminated
  • Thyroid-Associated Ophthalmopathy
  • Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
  • Alicante, Spain
    Hospital General d'Alacant
Jun 1, 2020

Malignant Carcinoid Syndrome Trial in Tampa (lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR)

Terminated
  • Malignant Carcinoid Syndrome
  • lanreotide Autogel (somatostatin analogue)
  • Sandostatin long acting release (LAR) Depot (somatostatin analogue)
  • Tampa, Florida
    Larry Kvols, MD
Apr 28, 2020

Carcinoma, Hepatocellular, Neuroendocrine Tumors Trial in Aarhus (Sorafenib, Radiofrequency ablation (RFA) or surgery,

Completed
  • Carcinoma, Hepatocellular
  • Neuroendocrine Tumors
  • Aarhus, Aarhus C, Denmark
    Department of Hepatology and Gastroenterology
Apr 27, 2021

Switching From Octreotide to Lanreotide - A Look Back at

Completed
  • Neuroendocrine Tumors
  • Data collection
  • Tampa, Florida
  • +7 more
Jun 1, 2020

Intestinal Obstruction, Carcinoma, Peritoneal Tumors Trial in Belgium, France, Netherlands (Lanreotide (microparticle

Completed
  • Intestinal Obstruction
  • +2 more
  • Lanreotide (microparticle formulation)
  • Placebo
  • Bruxelles, Belgium
  • +52 more
Nov 4, 2020

Acromegaly Trial in France, Switzerland (Lanreotide (Autogel formulation))

Completed
  • Acromegaly
  • Lanreotide (Autogel formulation)
  • Amiens, France
  • +16 more
Mar 30, 2020

Small Intestinal NET, Carcinoid Heart Disease Trial (Telotristat Ethyl, Lanreotide)

Withdrawn
  • Small Intestinal NET
  • Carcinoid Heart Disease
  • Telotristat Ethyl
  • Lanreotide
  • (no location specified)
Jan 30, 2020

Autosomal Dominant Polycystic Kidney Disease (ADPKD Trial in Paris (Lanreotide, saline)

Completed
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD
  • Paris, France
    Necker hospital
Nov 15, 2019

Prostate Cancer Trial in Orbassano ( TO) (Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and

Terminated
Has Results
  • Prostate Cancer
  • Lanreotide, non steroidal anti androgens and LHRH-a
  • Non steroidal anti androgens and LHRH-a
  • Orbassano ( TO), Italy
    A.O. S. Luigi Gonzaga
Nov 21, 2019

United Kingdom Patient Preference Study of Somatuline Autogel

Completed
  • Neuroendocrine Tumours (NET)
    • Birmingham, United Kingdom
    • +4 more
    Jul 5, 2022

    Acromegaly Trial in Munich (lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval)

    Completed
    • Acromegaly
    • lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
    • Munich, Germany
      Klinikum Innenstadt
    Nov 21, 2019

    Acromegaly Trial in Mexico City (lanreotide (Autogel formulation))

    Withdrawn
    • Acromegaly
    • lanreotide (Autogel formulation)
    • Mexico City, Mexico
      Centro Médico Nacional Siglo XXI, IMSS
    Aug 1, 2019

    Acromegaly, GEP-NET Trial in Worldwide (Debio 4126, Sandostatin LAR, Somatuline ATG)

    Recruiting
    • Acromegaly
    • GEP-NET
    • Debio 4126
    • +2 more
    • Copenaghen, Denmark
    • +34 more
    Jan 27, 2023

    Acromegaly Trial in Westmead (Lanreotide (Autogel formulation))

    Completed
    • Acromegaly
    • Lanreotide (Autogel formulation)
    • Westmead, New South Wales, Australia
      Westmead Hospital
    Aug 14, 2019

    Acromegaly Trial in Worldwide (Paltusotine, Placebo)

    Completed
    • Acromegaly
    • Los Angeles, California
    • +44 more
    Jul 13, 2021

    Community-based Neuroendocrine Tumor (NET) Research Study

    Completed
    • Gastroenteropancreatic Neuroendocrine Tumors
      • Sedona, Arizona
      • +11 more
      Jun 25, 2020

      Acromegaly Trial in United States (Somatuline Autogel (lanreotide acetate), Home administration)

      Completed
      Has Results
      • Acromegaly
      • Somatuline Autogel (lanreotide acetate)
      • Home administration
      • La Mesa, California
      • +12 more
      Nov 4, 2020

      Neuroendocrine Tumour With Carcinoid Symptoms Trial in Denmark, Norway, Sweden (lanreotide (Autogel formulation))

      Completed
      Has Results
      • Neuroendocrine Tumour With Carcinoid Symptoms
      • lanreotide (Autogel formulation)
      • Aarhus, Denmark
      • +9 more
      Nov 21, 2019

      Neuroendocrine Tumors Trial in Seoul (Lanreotide)

      Unknown status
      • Neuroendocrine Tumors
      • Lanreotide
      • Seoul, Korea, Republic of
        Youngsuk Park
      May 17, 2019

      Intestinal Obstruction Trial in Italy (lanreotide (Autogel formulation))

      Terminated
      Has Results
      • Intestinal Obstruction
      • lanreotide (Autogel formulation)
      • Gallipoli, Lecce, Italy
      • +12 more
      Nov 21, 2019

      Carcinoid Syndrome, Carcinoid, Carcinoid Tumor Trial in Newport Beach, Lexington, Stony Brook (Randomized: 40 mg Paltusotine,

      Recruiting
      • Carcinoid Syndrome
      • +8 more
      • Randomized: 40 mg Paltusotine
      • Randomized: 80 mg Paltusotine
      • Newport Beach, California
      • +5 more
      Jan 3, 2023

      Acromegaly Trial in Worldwide (Lanreotide (Autogel formulation))

      Completed
      • Acromegaly
      • Lanreotide (Autogel formulation)
      • Birmingham, Alabama
      • +28 more
      Aug 1, 2019

      Intestinal Obstruction Trial in Belgium (Lanreotide Autogel)

      Completed
      Has Results
      • Intestinal Obstruction
      • Lanreotide Autogel
      • Aalst, Belgium
      • +16 more
      Apr 4, 2019

      Gastroenteropancreatic Neuroendocrine Tumors Trial in Austria, Germany (Lanreotide Autogel 120 mg, Temozolomide (TMZ))

      Completed
      Has Results
      • Gastroenteropancreatic Neuroendocrine Tumors
      • Lanreotide Autogel 120 mg
      • Temozolomide (TMZ)
      • Vienna, Austria
      • +9 more
      Feb 6, 2019

      Gastro-entero-pancreatic Neuroendocrine Tumors Trial in Meldola (Capecitabine, Lu-PRRT, SS-LAR)

      Active, not recruiting
      • Gastro-entero-pancreatic Neuroendocrine Tumors
      • Meldola, FC, Italy
        Irst Irccs
      Feb 25, 2021